Pharma Two B uses its expertise in drug pharmacology and drug delivery systems, with the aim to optimize the efficacy, safety and availability and develop novel formulations for previously approved drugs. We aim to make better pharmaceutical products with significant benefits for patients.
Pharma Two B’s lead product candidate is P2B001, which is being developed as a novel treatment for early stage Parkinson’s Disease (PD). P2B001 is a unique combination of two previously approved PD drugs with complementary mechanisms of action. The formulation of the combination was adapted to allow extended mutual activity, leading to enhanced synergistic effects. Data from P2B001 phase II clinical trial implies that P2B001 may allow for a meaningful therapeutic effect in low doses with a favorable safety profile. For further information about P2B001 please click here
P2B001 is now in phase III clinical trial in the US and Europe.
Pharma Two B’s pipeline is aimed at additional investigational products related to CNS and other diseases, where there continues to be a significant unmet patient need for effective, safe and convenient products.